Prograf Blog

Watson Gets Approval for Generic Transplant Drug

Posted 3 Jul 2010 by Drugs.com

From Associated Press (July 2, 2010) MORRISTOWN, N.J. – Watson Pharmaceuticals Inc. said Friday it received approval to sell a generic version of the drug Prograf, which is used to prevent rejection of transplanted organs. The Food and Drug Administration approved Watson's generic version of Prograf, or tacrolimus, in 5-milligram capsules. Watson said it will start shipping the drug immediately. The brand-name version is made by Astellas Pharma, and Watson said U.S. sales totaled $108 million the 12 months ended in May. Prograf is used to suppress the immune system and prevent the rejection of transplanted livers, kidneys, and hearts.   Read more

Related support groups: Prograf